We independently reproduced a study comparing effects of GLP‐1RA versus dipeptidyl peptidase‐4 inhibitors (DPP4‐i) on CLRD outcomes among patients with T2DM and prior CLRD. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.